Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients

Hiromichi Matsuoka, Tokuzo Arao, Chihiro Makimura, Masayuki Takeda, Hidemi Kiyota, Junji Tsurutani, Yoshihiko Fujita, Kazuko Matsumoto, Hideharu Kimura, Masatomo Otsuka, Atsuko Koyama, Chiyo Imamura, Yusuke Tanigawara, Takeharu Yamanaka, Kyoko Tanaka, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Genetic differences in individuals with regard to opioid-receptor signaling create clinical difficulties for opioid treatment; consequently, useful pharmacodynamic and predictive biomarkers are needed. In this prospective study, we studied gene expression changes in peripheral blood leukocytes using a microarray and real-time RT-PCR analysis to identify pharmacodynamic biomarkers for monitoring the effect of morphine in a cohort of opioid-treatment-naïve cancer patients. We also examined genetic variations in opioid receptor mu 1 (OPRM1, 118A→G) and catechol-O-methyltransferase (COMT, 472G→A) to evaluate predictive biomarkers of the treatment outcome of morphine. The plasma concentration of morphine was measured using a liquid chromatography-tandem mass spectrometry method. Microarray analysis revealed that the mRNA expression levels of arrestin β 1 (ARRB1) were significantly down-regulated by morphine treatment. Real-time RT-PCR analysis against independent samples confirmed the results (P=0.003) and changes during treatment were negatively correlated with the plasma morphine concentration (R=-0.42). No correlation was observed between the genotype of OPRM1 and morphine treatment; however, the plasma concentration of morphine and the required dose of morphine were significantly lower for the A/A genotype of COMT (vs. A/G+G/G, P=0.008 and 0.03). We found that changes in the expression of ARRB1 may be a novel pharmacodynamic biomarker and the COMT 472G→A genotype may be a predictive biomarker of the response to morphine treatment.

Original languageEnglish
Pages (from-to)1393-1399
Number of pages7
JournalOncology Reports
Volume27
Issue number5
DOIs
Publication statusPublished - 2012 May

Fingerprint

Arrestin
Catechol O-Methyltransferase
Morphine
Biomarkers
Neoplasms
Therapeutics
Genotype
Opioid Analgesics
Real-Time Polymerase Chain Reaction
mu Opioid Receptor
Opioid Receptors
Microarray Analysis
Tandem Mass Spectrometry
Individuality
Liquid Chromatography
Leukocytes
Prospective Studies
Gene Expression
Messenger RNA

Keywords

  • Arrestin
  • Catechol-O-methyltransferase
  • Microarray
  • Morphine
  • Opioid receptor μ 1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. / Matsuoka, Hiromichi; Arao, Tokuzo; Makimura, Chihiro; Takeda, Masayuki; Kiyota, Hidemi; Tsurutani, Junji; Fujita, Yoshihiko; Matsumoto, Kazuko; Kimura, Hideharu; Otsuka, Masatomo; Koyama, Atsuko; Imamura, Chiyo; Tanigawara, Yusuke; Yamanaka, Takeharu; Tanaka, Kyoko; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Oncology Reports, Vol. 27, No. 5, 05.2012, p. 1393-1399.

Research output: Contribution to journalArticle

Matsuoka, H, Arao, T, Makimura, C, Takeda, M, Kiyota, H, Tsurutani, J, Fujita, Y, Matsumoto, K, Kimura, H, Otsuka, M, Koyama, A, Imamura, C, Tanigawara, Y, Yamanaka, T, Tanaka, K, Nishio, K & Nakagawa, K 2012, 'Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients', Oncology Reports, vol. 27, no. 5, pp. 1393-1399. https://doi.org/10.3892/or.2012.1660
Matsuoka, Hiromichi ; Arao, Tokuzo ; Makimura, Chihiro ; Takeda, Masayuki ; Kiyota, Hidemi ; Tsurutani, Junji ; Fujita, Yoshihiko ; Matsumoto, Kazuko ; Kimura, Hideharu ; Otsuka, Masatomo ; Koyama, Atsuko ; Imamura, Chiyo ; Tanigawara, Yusuke ; Yamanaka, Takeharu ; Tanaka, Kyoko ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. In: Oncology Reports. 2012 ; Vol. 27, No. 5. pp. 1393-1399.
@article{d0ac8f12b6014185a4d8bef625ef0135,
title = "Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients",
abstract = "Genetic differences in individuals with regard to opioid-receptor signaling create clinical difficulties for opioid treatment; consequently, useful pharmacodynamic and predictive biomarkers are needed. In this prospective study, we studied gene expression changes in peripheral blood leukocytes using a microarray and real-time RT-PCR analysis to identify pharmacodynamic biomarkers for monitoring the effect of morphine in a cohort of opioid-treatment-na{\"i}ve cancer patients. We also examined genetic variations in opioid receptor mu 1 (OPRM1, 118A→G) and catechol-O-methyltransferase (COMT, 472G→A) to evaluate predictive biomarkers of the treatment outcome of morphine. The plasma concentration of morphine was measured using a liquid chromatography-tandem mass spectrometry method. Microarray analysis revealed that the mRNA expression levels of arrestin β 1 (ARRB1) were significantly down-regulated by morphine treatment. Real-time RT-PCR analysis against independent samples confirmed the results (P=0.003) and changes during treatment were negatively correlated with the plasma morphine concentration (R=-0.42). No correlation was observed between the genotype of OPRM1 and morphine treatment; however, the plasma concentration of morphine and the required dose of morphine were significantly lower for the A/A genotype of COMT (vs. A/G+G/G, P=0.008 and 0.03). We found that changes in the expression of ARRB1 may be a novel pharmacodynamic biomarker and the COMT 472G→A genotype may be a predictive biomarker of the response to morphine treatment.",
keywords = "Arrestin, Catechol-O-methyltransferase, Microarray, Morphine, Opioid receptor μ 1",
author = "Hiromichi Matsuoka and Tokuzo Arao and Chihiro Makimura and Masayuki Takeda and Hidemi Kiyota and Junji Tsurutani and Yoshihiko Fujita and Kazuko Matsumoto and Hideharu Kimura and Masatomo Otsuka and Atsuko Koyama and Chiyo Imamura and Yusuke Tanigawara and Takeharu Yamanaka and Kyoko Tanaka and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2012",
month = "5",
doi = "10.3892/or.2012.1660",
language = "English",
volume = "27",
pages = "1393--1399",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients

AU - Matsuoka, Hiromichi

AU - Arao, Tokuzo

AU - Makimura, Chihiro

AU - Takeda, Masayuki

AU - Kiyota, Hidemi

AU - Tsurutani, Junji

AU - Fujita, Yoshihiko

AU - Matsumoto, Kazuko

AU - Kimura, Hideharu

AU - Otsuka, Masatomo

AU - Koyama, Atsuko

AU - Imamura, Chiyo

AU - Tanigawara, Yusuke

AU - Yamanaka, Takeharu

AU - Tanaka, Kyoko

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2012/5

Y1 - 2012/5

N2 - Genetic differences in individuals with regard to opioid-receptor signaling create clinical difficulties for opioid treatment; consequently, useful pharmacodynamic and predictive biomarkers are needed. In this prospective study, we studied gene expression changes in peripheral blood leukocytes using a microarray and real-time RT-PCR analysis to identify pharmacodynamic biomarkers for monitoring the effect of morphine in a cohort of opioid-treatment-naïve cancer patients. We also examined genetic variations in opioid receptor mu 1 (OPRM1, 118A→G) and catechol-O-methyltransferase (COMT, 472G→A) to evaluate predictive biomarkers of the treatment outcome of morphine. The plasma concentration of morphine was measured using a liquid chromatography-tandem mass spectrometry method. Microarray analysis revealed that the mRNA expression levels of arrestin β 1 (ARRB1) were significantly down-regulated by morphine treatment. Real-time RT-PCR analysis against independent samples confirmed the results (P=0.003) and changes during treatment were negatively correlated with the plasma morphine concentration (R=-0.42). No correlation was observed between the genotype of OPRM1 and morphine treatment; however, the plasma concentration of morphine and the required dose of morphine were significantly lower for the A/A genotype of COMT (vs. A/G+G/G, P=0.008 and 0.03). We found that changes in the expression of ARRB1 may be a novel pharmacodynamic biomarker and the COMT 472G→A genotype may be a predictive biomarker of the response to morphine treatment.

AB - Genetic differences in individuals with regard to opioid-receptor signaling create clinical difficulties for opioid treatment; consequently, useful pharmacodynamic and predictive biomarkers are needed. In this prospective study, we studied gene expression changes in peripheral blood leukocytes using a microarray and real-time RT-PCR analysis to identify pharmacodynamic biomarkers for monitoring the effect of morphine in a cohort of opioid-treatment-naïve cancer patients. We also examined genetic variations in opioid receptor mu 1 (OPRM1, 118A→G) and catechol-O-methyltransferase (COMT, 472G→A) to evaluate predictive biomarkers of the treatment outcome of morphine. The plasma concentration of morphine was measured using a liquid chromatography-tandem mass spectrometry method. Microarray analysis revealed that the mRNA expression levels of arrestin β 1 (ARRB1) were significantly down-regulated by morphine treatment. Real-time RT-PCR analysis against independent samples confirmed the results (P=0.003) and changes during treatment were negatively correlated with the plasma morphine concentration (R=-0.42). No correlation was observed between the genotype of OPRM1 and morphine treatment; however, the plasma concentration of morphine and the required dose of morphine were significantly lower for the A/A genotype of COMT (vs. A/G+G/G, P=0.008 and 0.03). We found that changes in the expression of ARRB1 may be a novel pharmacodynamic biomarker and the COMT 472G→A genotype may be a predictive biomarker of the response to morphine treatment.

KW - Arrestin

KW - Catechol-O-methyltransferase

KW - Microarray

KW - Morphine

KW - Opioid receptor μ 1

UR - http://www.scopus.com/inward/record.url?scp=84863248608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863248608&partnerID=8YFLogxK

U2 - 10.3892/or.2012.1660

DO - 10.3892/or.2012.1660

M3 - Article

VL - 27

SP - 1393

EP - 1399

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -